Alexion, seeking to broaden business, to buy Portola for $1.4B

Share

Alexion will buy Portola Pharmaceuticals for $1.44B, the latest deal aimed at expanding its business beyond Soliris. Alexion is betting it can increase sales of Portola’s Andexxa, which is used to reverse the effects of blood thinning drugs like Xarelto and Eliquis. Since winning U.S. approval in 2018, Portola has had trouble building a market for Andexxa.

Read the full article at biopharmadive.com…

Share

Comments are closed.